Shanghai Junshi Biosciences Co Shares float
What is the Shares float of Shanghai Junshi Biosciences Co?
The Shares float of Shanghai Junshi Biosciences Co., Ltd. is 563.057M 256.76%
What is the definition of Shares float?
Shares float is the portion of shares of a corporation that are in the hands of public investors as opposed to locked-in stock.
= annual shares outstanding - closely held shares
Shares float represents the portion of shares of a corporation that are in the hands of public investors as opposed to locked-in stock held by promoters, company officers, controlling-interest investors, or government. This number is sometimes seen as a better way of calculating market capitalization because it provides a more accurate reflection of what public investors consider the company to be worth. In this context, the float may refer to all the shares outstanding that can be publicly traded
The float is calculated by subtracting the locked-in shares from outstanding shares. Stocks with smaller floats tend to be more volatile than those with larger floats. In general, the large holdings of founding shareholders, corporate cross-holdings, and government holdings in partially privatized companies are excluded when calculating the size of a public float.
Shares float of companies in the Health Care sector on OTC compared to Shanghai Junshi Biosciences Co
What does Shanghai Junshi Biosciences Co do?
Shanghai Junshi Biosciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of various drugs in the therapeutic areas of oncology, metabolic, autoimmune, neurologic, and infectious diseases in the People's Republic of China. The company offers JS001, a recombinant humanized anti-PD-1 monoclonal antibody under the trade name of TUOYI for the indication of melanoma, mucosal melanoma, soft tissue sarcoma, nasopharyngeal carcinoma, urothelial carcinoma, non-small cell lung carcinoma, triple negative breast carcinoma, esophageal squamous cell carcinoma, and hepatocellular carcinoma. It is also developing UBP1211, a biosimilar of Humira for the treatment of rheumatoid arthritis, ankylosing spondylitis, and psoriasis; JS002, a recombinant humanized anti-PCSK9 monoclonal antibody for treating hyperlipidemia; UBP1213, a recombinant humanized anti-BLyS monoclonal antibody for injection. In addition, the company is developing JS501, a biosimilar of Avastin; and JS003, a recombinant humanized anti-PD-L1 monoclonal antibody for injection; JS101, a pan-CDK inhibitor; TAB004/JS004, a recombinant humanized anti-BTLA monoclonal antibody for injection; and JS005, a recombinant humanized anti-IL-17A monoclonal antibody for injection. It has an agreement with Eli Lilly and Company to co-develop therapeutic antibodies for the potential prevention and treatment of COVID-19, the disease caused by the SARS-CoV-2 novel coronavirus as well as Coherus Biosciences, Inc. for the development and commercialization of toripalimab, Junshi Biosciences' anti-PD-1 antibody. Shanghai Junshi Biosciences Co., Ltd. was founded in 2012 and is headquartered in Shanghai, People's Republic of China.
Companies with shares float similar to Shanghai Junshi Biosciences Co
- China Oil Gangran has Shares float of 561.441M 22.16%
- Power of Canada has Shares float of 562.284M 90.44%
- Power of Canada has Shares float of 562.284M 90.44%
- Centene has Shares float of 562.381M 136.93%
- IDBI Bank has Shares float of 562.685M 5.23%
- Shandong International Trust Co has Shares float of 563.022M 48.34%
- Shanghai Junshi Biosciences Co has Shares float of 563.057M 256.76%
- Octopus Renewables Infrastructure Trust PLC has Shares float of 563.221M 99.70%
- Boill Healthcare has Shares float of 564.168M 41.54%
- China Baoli Technologies has Shares float of 564.317M 101.09%
- Computershare has Shares float of 564.402M 93.49%
- Computershare has Shares float of 564.445M 93.49%
- Newborn Town has Shares float of 565.052M 51.42%